Revance Therapeutics, Inc. revenue for the last year amounted to 234.04 M USD, the most of which — 221.79 M USD — came from its highest performing source at the moment, Product, the year earlier bringing 125.58 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Revance Therapeutics, Inc. 234.04 M USD, and the year before that — 132.56 M USD.